References
- Ko JK, Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis and current therapy. Curr Pharm Des 2014;20:1082–96
- Furlan R, Ardizzone S, Palazzolo L, et al. Sympathetic overactivity in active ulcerative colitis: effects of clonidine. Am J Physiol Regul Integr Comp Physiol 2006;290:R224–32
- Straub RH, Wiest R, Strauch UG, et al. The role of the sympathetic nervous system in intestinal inflammation. Gut 2006;55:1640–9
- Ben-Horin S, Chowers Y. Neuroimmunology of the gut: physiology, pathology, and pharmacology. Curr Opin Pharmacol 2008;8:490–5
- Arlander E, Ost A, Stahlberg D, Lofberg R. Ropivacaine gel in active distal ulcerative colitis and proctitis – a pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther 1996;10:73–81
- Martinsson T, Ljung T, Rubio C, Hellstrom PM. Beneficial effects of ropivacaine in rat experimental colitis. J Pharmacol Exp Ther 1999;291:642–7
- Lawrance IC. Topical agents for idiopathic distal colitis and proctitis. J Gastroenterol Hepatol 2011;26:36–43
- Jung Y, Kim YM. What should be considered on design of a colon-specific prodrug? Expert Opin Drug Deliv 2010;7:245–58
- Larsen C, Harboe E, Johansen M, Olesen HP. Macromolecular prodrugs. XVI. Colon-targeted delivery – comparison of the rate of release of naproxen from dextran ester prodrugs in homogenates of various segments of the pig gastrointestinal (GI) tract. Pharm Res 1989;6:995–9
- Larsen C, Jensen BH, Olesen HP. Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig. Acta Pharm Nord 1991;3:71–6
- McLeod AD, Friend DR, Tozer TN. Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents. J Pharm Sci 1994;83:1284–8
- Jung YJ, Lee JS, Kim HH, et al. Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5-aminosalicylic acid. Arch Pharm Res 1998;21:179–86
- Lee JS, Jung YJ, Doh MJ, Kim YM. Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Dev Ind Pharm 2001;27:331–6
- Sery TW, Hehre EJ. Degradation of dextrans by enzymes of intestinal bacteria. J Bacteriol 1956;71:373–80
- Andrew DM. Dextran prodrugs for colonic-specific drug delivery. In: Friend DR, ed. Oral colon specific drug delivery. Boca Raton, FL: CRC Press; 1992:213–31
- Nielsen LS, Weibel H, Johansen M, Larsen C. Macromolecular prodrugs. XX. Factors influencing model dextranase-mediated depolymerization of dextran derivatives in vitro. Acta Pharm Nord 1992;4:23–30
- Lee Y, Kim IH, Kim J, et al. Evaluation of dextran-flufenamic acid ester as a polymeric colon-specific prodrug of flufenamic acid, an anti-inflammatory drug, for chronotherapy. J Drug Target 2011;19:336–43
- Thomson AB. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1991;5:449–70
- Szoke A, Hayton WL, Schultz IR. Quantification of benzocaine and its metabolites in channel catfish tissues and fluids by HPLC. J Pharm Biomed Anal 1997;16:69–75
- de Araujo DR, Padula C, Cereda CM, et al. Bioadhesive films containing benzocaine: correlation between in vitro permeation and in vivo local anesthetic effect. Pharm Res 2010;27:1677–86
- McLeod AD, Friend DR, Tozer TN. Synthesis and chemical stability of glucocorticoid-dextran esters: potential prodrugs for colon-specific delivery. Int J Pharm 1993;92:105–14
- Hong S, Yum S, Yoo HJ, et al. Colon-targeted cell-permeable NFkappaB inhibitory peptide is orally active against experimental colitis. Mol Pharm 2012;9:1310–19
- Kim H, Kong H, Choi B, et al. Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease. Pharm Res 2005;22:1499–509
- Khan NA, Kruse JA. Methemoglobinemia induced by topical anesthesia: a case report and review. Am J Med Sci 1999;318:415–18
- Jung Y, Kim HH, Kim H, et al. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis. Eur J Pharm Sci 2006;28:26–33
- Lee Y, Kim J, Kim H, et al. N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties. J Pharm Sci 2012;101:1831–42